US Pharma MarketingADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buy
On the heels of a strong showing for the drug earlier this year, Pfizer is padding the case for the GLP-1 receptor agonist it picked up in its $10 billion purchase of obesity biotech Metsera. On the heels of a strong showing for the drug earlier this year, Pfizer is padding the case for the GLP-1 receptor agonist it picked up in its $10 billion purchase of obesity biotech Metsera. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene…
On the heels of a strong showing for the drug earlier this year, Pfizer is padding the case for the GLP-1 receptor agonist it picked up in its $10 billion purchase of obesity biotech Metsera.
Source: FierceBiotech